Clearpoint Neuro, INC Form 4 insider transactions

ClearPoint Neuro's CEO, Joseph Burnett, received 132,841 restricted stock units (RSUs) on March 3, 2025, vesting over a three-year period.

ClearPoint Neuro's Chief Business Officer, Jeremy Stigall, reports a transaction involving the delivery of shares to cover tax withholding obligations related to the vesting of restricted stock.

ClearPoint Neuro's CEO, Joseph Burnett, reports acquiring 251 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.53 per share.

ClearPoint Neuro's Chief Business Officer, Jeremy L. Stigall, acquired 251 shares of common stock through the company's Employee Stock Purchase Plan.

Mazin Sabra, Chief Operating Officer of ClearPoint Neuro, Inc., acquired 784 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) on December 31, 2024.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports acquiring 1,949 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.53 per share.

Director Linda M. Liau acquired 193 shares of ClearPoint Neuro, Inc. common stock on January 2, 2025, as payment for director fees.

Director Timothy T. Richards acquired 725 shares of ClearPoint Neuro stock as compensation for director fees.

Director R. John Fletcher acquired 375 shares of ClearPoint Neuro, Inc. as part of his compensation plan.

Director Pascal E. R. Girin acquired 406 shares of ClearPoint Neuro stock as compensation for director fees.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, disposed of shares to cover tax obligations related to vesting restricted stock.

Director Linda M. Liau acquired 264 shares of ClearPoint Neuro, Inc. common stock on October 1, 2024, in lieu of fees owed under the company's Non-Employee Director Compensation Plan.

Director Timothy T. Richards acquired 995 shares of ClearPoint Neuro, Inc. common stock at $11.21 per share in lieu of fees owed under the company's Non-Employee Director Compensation Plan.

Director Pascal E. R. Girin acquired 557 shares of ClearPoint Neuro, Inc. common stock on October 1, 2024, in lieu of fees owed under the company's Non-Employee Director Compensation Plan.

Director R. John Fletcher acquired 515 shares of ClearPoint Neuro, Inc. common stock on October 1, 2024, in lieu of fees owed under the company's Non-Employee Director Compensation Plan.

ClearPoint Neuro's Chief Business Officer, Jeremy Stigall, disposed of 420 shares of common stock to cover tax obligations related to vesting restricted stock.

Danilo D'Alessandro, CFO of ClearPoint Neuro, sold 1,191 shares of common stock on August 20, 2024, to cover tax withholding obligations related to vesting restricted stock.

CEO Joseph Burnett of ClearPoint Neuro, Inc. reports disposition of shares to cover tax obligations related to vesting restricted stock.

Mazin Sabra, Chief Operating Officer of ClearPoint Neuro, Inc., reports the acquisition of 767 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.58 per share.

L. Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, Inc., acquired 3,500 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.58 per share.

ClearPoint Neuro's CEO, Joseph Michael Burnett, acquired 3,500 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.58 per share.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports acquiring 1,913 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.58 per share.

Director Linda M. Liau acquired 550 shares of ClearPoint Neuro, Inc. common stock on July 1, 2024, as payment for director fees.

Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., acquired 1,333 shares of common stock on July 1, 2024, in payment of director fees.

Director R. John Fletcher acquired 1,072 shares of ClearPoint Neuro, Inc. common stock on July 1, 2024, in lieu of fees owed under the company's Non-Employee Director Compensation Plan.

Director Timothy Richards acquired 2,069 shares of ClearPoint Neuro common stock on July 1, 2024, in lieu of fees under the company's Non-Employee Director Compensation Plan.

Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, sold shares to cover tax obligations related to vesting restricted stock.

Danilo D'Alessandro, CFO of ClearPoint Neuro, sold 4,824 shares of common stock on June 10, 2024, to cover tax obligations related to vesting restricted stock.

CEO Joseph Burnett disposed of 14,003 shares of ClearPoint Neuro stock on June 10, 2024, to cover tax withholding obligations related to vesting restricted stock.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, acquired 65,252 restricted stock units on May 20, 2024, according to a Form 4 filing.